May 15, 2015 / 1:23 PM / 2 years ago

BUZZ-Trillium Therapeutics Inc: Oppenheimer starts with "outperform" rating

1 Min Read

** Canada-based drugmaker's shares up 11 pct at $20.60 premarket

** Oppenheimer & Co starts coverage with "outperform" rating and price target of $32

** Company could start testing its lead therapy, SIRPFc, in indications other than blood cancer in the next 12-18 months, analyst Christopher Marai writes in a note

** Marai says each of the upcoming trials could yield profound results

** Up to Thursday's close, the stock had more than doubled this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below